Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations.status: publishe
Objective: To update recommendations for the treatment of psoriatic arthritis with biological therap...
Objective: To update the evidence on the efficacy and safety of pharmacological agents in psoriatic ...
In 2015, both the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) an...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...
To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological tre...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacol...
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatme...
To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics an...
The aims of treatment for psoriatic arthritis (PsA) are to control inflammation, normalise functions...
Objective: To update recommendations for the treatment of psoriatic arthritis with biological therap...
Objective: To update the evidence on the efficacy and safety of pharmacological agents in psoriatic ...
In 2015, both the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) an...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...
To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological tre...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacol...
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatme...
To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics an...
The aims of treatment for psoriatic arthritis (PsA) are to control inflammation, normalise functions...
Objective: To update recommendations for the treatment of psoriatic arthritis with biological therap...
Objective: To update the evidence on the efficacy and safety of pharmacological agents in psoriatic ...
In 2015, both the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) an...